
Superpower peptides available for pre-order. Get first access.

Not FDA-approved
Immune & defense
Thymosin alpha-1
Also called Tα1, thymalfasin
Key takeaway
Thymosin alpha-1 is an immune-modulating peptide approved as thymalfasin (Zadaxin) in many countries but not in the United States. The 2025 TESTS trial of 1,089 patients with sepsis found 28-day mortality of 23.4% on thymosin alpha-1 versus 24.1% on placebo (hazard ratio 0.97, 95% CI 0.76 to 1.24, p = 0.82, as corrected in 2025). Hepatitis B trials are more encouraging, results are mixed overall, and none of it supports a general wellness use.
- Written by
- Nav SekhonResearch Lead
- Published
- April 18, 2026
- Last updated
- November 12, 2026
At a glance
| FDA status | Not FDA-approved in the U.S.; approved as thymalfasin (Zadaxin) in many other countries |
| What it is | Immune-modulating peptide originally from thymus extract |
| Research | Real human trials in hepatitis and sepsis, but results are mixed and a key recent trial was negative |
| Wellness use | No evidence for a general wellness or longevity use |
| Evidence strength | Moderate research |
What is thymosin alpha-1?
Thymosin alpha-1 (abbreviated Tα1) is a 28-amino acid peptide originally isolated from thymus-gland extract, where immune cells mature. It acts as an immune modulator and is an approved drug in more than 35 countries1 under the name thymalfasin (brand Zadaxin), used for chronic hepatitis and as an immune adjunct. In the United States, it is not approved and is sold through wellness and compounding channels for immune support.
How does it work?
Thymosin alpha-1 modulates the immune system in several ways:
- Influencing the maturation and function of T-cells
- Boosting signals such as interferon-gamma and interleukin-2
- Enhancing natural killer-cell activity, partly through Toll-like receptor pathways
In a 2004 laboratory and mouse study, it activated dendritic cells through Toll-like receptor signaling2, raising interleukin-12 and Th1 immunity, and protected transplanted mice from the lung fungus Aspergillus.
This mechanism is supported by laboratory and clinical immune data, such as improved immune-cell markers in sepsis studies. This describes how it acts on the immune system, separate from whether it improves outcomes in a given condition.
Is it FDA-approved?
No, not in the United States. It is approved and marketed as thymalfasin (Zadaxin) in many other countries for chronic hepatitis B and C and as an immune/vaccine adjunct. It was not among the peptides reviewed favorably at the 2026 FDA compounding advisory meetings. Superpower does not prescribe, sell, or facilitate access to thymosin alpha-1.
What does the research show?
It has real human trials, with mixed results, in specific immune conditions, not general wellness. The trials and meta-analyses below report outcome figures.
| Condition and trial | Patients | Result |
| Chronic hepatitis B, randomized trial3 comparing thymosin alpha-1 with no treatment | 98 | Complete virological response reached 40.6% after a 26-week course versus 9.4% in controls (p = 0.004); a 52-week course was not significantly better than control |
| Chronic hepatitis B, 2008 meta-analysis4 of 4 randomized trials comparing thymosin alpha-1 with interferon-alpha | 199 | Virological response did not differ significantly from interferon at the end of 6 months of treatment; 6 months after treatment ended, it favored thymosin alpha-1 (odds ratio 3.71, 95% CI 2.05 to 6.71) |
| Chronic hepatitis C, randomized pilot trial5 adding thymosin alpha-1 to interferon-alpha 2b | 41 | Higher virological response at the end of 6 months of treatment than interferon alone (p = 0.03); sustained response 6 months later did not differ |
| Sepsis, earlier multicenter trial6 | 361 | Borderline mortality benefit suggested: 26.0% versus 35.0% at 28 days (p = 0.062) |
| Sepsis, larger double-blind Phase 3 TESTS trial7 | 1,089 | No mortality benefit: 28-day mortality 23.4% on thymosin alpha-1 versus 24.1% on placebo (hazard ratio 0.97, 95% CI 0.76 to 1.24, p = 0.82, per the 2025 correction8) |
| Hospitalized adults with COVID-19, 2023 meta-analysis9 of 9 studies | 5,352 | No overall effect on mortality (risk ratio 1.03, 95% CI 0.60 to 1.75, p = 0.92); subgroups with severe or critical disease, or a mean age over 60, had lower mortality |
In chronic hepatitis B, a separate trial reported modest effects on viral and liver markers10. In sepsis, a 2025 meta-analysis11 found the apparent benefit disappeared in higher-quality studies. In COVID-19, the 2023 meta-analysis authors did not support its use9 in hospitalized adults. In cancer, a 2019 review describes its use alongside chemotherapy and immunotherapy12 in melanoma, liver cancer, and lung cancer, and its potential pairing with checkpoint inhibitors. So real human efficacy exists for some immune and antiviral uses but is mixed, and none of it supports a general wellness or longevity use.
More for immune & defense
Sources: a hepatitis B trial (Iino et al., Journal of Viral Hepatitis, 2005, DOI: 10.1111/j.1365-2893.2005.00633.x10); the ETASS sepsis trial (Wu et al., Critical Care, 2013, DOI: 10.1186/cc119326); the Phase 3 TESTS sepsis trial (BMJ, 2025, DOI: 10.1136/bmj-2024-0825837); and a 2025 meta-analysis (Frontiers in Cellular and Infection Microbiology, DOI: 10.3389/fcimb.2025.167395911), all indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.